Ionis Pharmaceuticals, Inc. (IONS) Phase 3 IgAN Study Meets Interim Primary Endpoint
Ionis reported that partner Roche’s Phase 3 IMAgINATION study of sefaxersen in IgA nephropathy met its prespecified interim primary endpoint, showing statistically significant and clinically meaningful proteinuria reduction vs placebo at 37 weeks.Material DetailsContext by AI AnalystThis is a mid-t…